UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
Under the Securities Exchange Act of 1934

(AMENDMENT NO. 1)

ENANTA PHARMACEUTICALS, INC.
(Name of Issuer)

COMMON STOCK, PAR VALUE $0.01 PER SHARE
(Title of Class of Securities)

29251M106
(CUSIP Number)

SEPTEMBER 30, 2024
(Date of event which requires filing of this statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     o Rule 13d-1(b)

     þ Rule 13d-1(c)

     o Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                     
CUSIP No.
 
29251M106

SCHEDULE 13G

Page  
2
  of   
10

1
 NAMES OF REPORTING PERSONS
 
 Millennium Management LLC
2
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 (a)   o
 (b)   o
3
 SEC USE ONLY
4
 CITIZENSHIP OR PLACE OF ORGANIZATION

 Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5
 SOLE VOTING POWER

 -0-
6
 SHARED VOTING POWER

 731,295
 
7
 SOLE DISPOSITIVE POWER

 -0-
 
8
 SHARED DISPOSITIVE POWER

 731,295
 
9
 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 731,295
10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 o
11
 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 3.5%
12 TYPE OF REPORTING PERSON

 
OO


                     
CUSIP No.
 
29251M106

SCHEDULE 13G

Page  
3
  of   
10

1
 NAMES OF REPORTING PERSONS
 
 Millennium Group Management LLC
2
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 (a)   o
 (b)   o
3
 SEC USE ONLY
4
 CITIZENSHIP OR PLACE OF ORGANIZATION

 Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5
 SOLE VOTING POWER

 -0-
6
 SHARED VOTING POWER

 731,295
 
7
 SOLE DISPOSITIVE POWER

 -0-
 
8
 SHARED DISPOSITIVE POWER

 731,295
 
9
 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 731,295
10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 o
11
 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 3.5%
12 TYPE OF REPORTING PERSON

 
OO


                     
CUSIP No.
 
29251M106

SCHEDULE 13G

Page  
4
  of   
10

1
 NAMES OF REPORTING PERSONS
 
 Israel A. Englander
2
 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 (a)   o
 (b)   o
3
 SEC USE ONLY
4
 CITIZENSHIP OR PLACE OF ORGANIZATION

 United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5
 SOLE VOTING POWER

 -0-
6
 SHARED VOTING POWER

 731,295
 
7
 SOLE DISPOSITIVE POWER

 -0-
 
8
 SHARED DISPOSITIVE POWER

 731,295
 
9
 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 731,295
10
 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 o
11
 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 3.5%
12
 TYPE OF REPORTING PERSON

 IN

                     
CUSIP No.
 
29251M106

 SCHEDULE 13G

Page  
5
  of   
10
 
Item 1.    
 
(a) Name of Issuer:
 
   
 
  Enanta Pharmaceuticals, Inc.
 
   
 
(b) Address of Issuer’s Principal Executive Offices:
 
   
 
 

500 Arsenal Street
Watertown, Massachusetts 02472

     
Item 2.
(a) Name of Person Filing:
 
(b) Address of Principal Business Office:
 
(c) Citizenship:
     
 
  Millennium Management LLC
399 Park Avenue
New York, New York 10022
Citizenship: Delaware
 
   
 
  Millennium Group Management LLC
399 Park Avenue
New York, New York 10022
Citizenship: Delaware
 
   
 
  Israel A. Englander
c/o Millennium Management LLC
399 Park Avenue
New York, New York 10022
Citizenship: United States
 
   
  (d) Title of Class of Securities:
common stock, par value $0.01 per share ("Common Stock")
 
  (e) CUSIP Number:
29251M106
 
 

Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

 
  (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
             
 
  (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
             
 
  (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
             
 
  (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
             
 
  (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
             
 
  (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                     
CUSIP No.
 
29251M106

 SCHEDULE 13G

Page  
6
  of   
10
             
 
  (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
             
 
  (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
             
 
  (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
             
 
  (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

Item 4. Ownership

   Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount Beneficially Owned:

   See response to Item 9 on each cover page.

(b) Percent of Class:   

   See response to Item 11 on each cover page.

 (c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote

   See response to Item 5 on each cover page.


                     
CUSIP No.
 
29251M106

 SCHEDULE 13G

Page  
7
  of   
10

(ii) Shared power to vote or to direct the vote

   See response to Item 6 on each cover page.

(iii) Sole power to dispose or to direct the disposition of

   See response to Item 7 on each cover page.

(iv) Shared power to dispose or to direct the disposition of

   See response to Item 8 on each cover page.

   The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

Item 5. Ownership of Five Percent or Less of a Class

   If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

Item 8. Identification and Classification of Members of the Group

    See Exhibit I.

Item 9. Notice of Dissolution of Group

    Not applicable.

Item 10. Certification 

   By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                     
CUSIP No.
 
29251M106

SCHEDULE 13G

Page  
8
  of   
10

Exhibits:

Exhibit I:  Joint Filing Agreement, dated as of October 16, 2024, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                     
CUSIP No.
 
29251M106

SCHEDULE 13G

Page  
9
  of   
10
                     
     

SIGNATURE

             

After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

Dated: October 16, 2024

MILLENNIUM MANAGEMENT LLC

By: /s/Gil Raviv

Name: Gil Raviv
Title:  Global General Counsel

 

MILLENNIUM GROUP MANAGEMENT LLC

By: /s/Gil Raviv

Name: Gil Raviv
Title:  Global General Counsel

 

/s/ Israel A. Englander

Israel A. Englander



Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Enanta Pharmaceuticals Charts.
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Enanta Pharmaceuticals Charts.

Enanta Pharmaceuticals Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 27 November 2024 (2 days ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 27 November 2024 (2 days ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 27 November 2024 (2 days ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 27 November 2024 (2 days ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 27 November 2024 (2 days ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 27 November 2024 (2 days ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 27 November 2024 (2 days ago) • Edgar (US Regulatory)
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Wednesday 27 November 2024 (3 days ago) • Edgar (US Regulatory)
Form 8-K - Current report
Monday 25 November 2024 (4 days ago) • Edgar (US Regulatory)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024
Monday 25 November 2024 (4 days ago) • Business Wire
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (2 weeks ago) • Edgar (US Regulatory)
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 17 October 2024 (1 month ago) • Edgar (US Regulatory)

More Enanta Pharmaceuticals Inc News Articles